Gen9 Obtains $21,000,000 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f681e682-48ea-4c1f-a05e-5042ab3f5b2c&Preview=1 - Date
4/25/2013 - Company Name
Gen9 - Mailing Address
500 Technology Square 1st Floor Cambridge, MA 01239 - Company Description
Synthetic Biology is poised to modernize trillion dollar industries by introducing genes that program microorganisms to produce pharmaceuticals, biofuels and chemicals. A small number of Gen9’s current production tools generate sufficient DNA content to, in principle, replace the world’s current annual output of synthetic genes. - Website
http://www.gen9bio.com - Transaction Type
Venture Equity - Transaction Amount
$21,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Gen9 will use these funds to further invest in product development and to expand the commercial infrastructure for its synthetic biology business. As part of this investment. - M&A Terms
- Venture Investor
Agilent Technologies
